Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States
Crossref DOI link: https://doi.org/10.1007/s10549-016-3978-6
Published Online: 2016-09-21
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Diaby, Vakaramoko
Adunlin, Georges
Ali, Askal A.
Zeichner, Simon B.
de Lima Lopes, Gilberto
Kohn, Christine G.
Montero, Alberto J.
License valid from 2016-09-21